How to Fight Insurance Denials for Pulmonary Hypertension Treatments

Pulmonary hypertension (PH)—especially pulmonary arterial hypertension (PAH, WHO Group 1), chronic thromboembolic PH (CTEPH, Group 4), and PH associated with interstitial lung disease (PH-ILD, Group 3)—is a progressive disease characterized by elevated blood pressure in the lung arteries. Treatment requires expensive, specialized medications: endothelin receptor antagonists (ERAs like bosentan, ambrisentan, macitentan), phosphodiesterase-5 inhibitors (PDE5i like sildenafil, tadalafil), riociguat (a soluble guanylate cyclase stimulator), prostacyclin pathway agents (epoprostenol, treprostinil, iloprost, selexipag), and the newest class, sotatercept (Winrevair), an activin signaling inhibitor. Denials are extremely common because these therapies cost tens of thousands to hundreds of thousands of dollars per year, insurers demand strict hemodynamic proof via right-heart catheterization (RHC), and many plans impose step-edits requiring documented failure of cheaper oral agents before approving parenteral prostacyclins or newer drugs. Understanding the exact criteria insurers use—and the evidence that counters their denials—can mean the difference between functional decline and sustained quality of life.

Why Insurers Deny Pulmonary Hypertension Therapies

1. "No invasive hemodynamic confirmation"

Most denials cite lack of RHC documentation showing mean pulmonary arterial pressure (mPAP) ≥20 mmHg at rest (the 2022 ESC/ERS threshold, lowered from the older ≥25 mmHg cutoff), pulmonary capillary wedge pressure (PCWP) ≤15 mmHg, and pulmonary vascular resistance (PVR) ≥2 Wood units—the triad that defines pre-capillary PH. Insurers reject echocardiography alone, labeling it "not medically necessary" without catheterization-proven disease.

2. "Step therapy not met"

Many plans require sequential trials: first an oral ERA or PDE5i monotherapy (often tadalafil or sildenafil because of lower cost), then combination oral therapy, and only then—if documented clinical worsening persists—parenteral prostacyclins, Uptravi (selexipag), riociguat, or sotatercept. The denial states "patient must try and fail formulary alternatives" even when guidelines support upfront combination or triple therapy for intermediate- or high-risk patients.

3. "Functional class / risk score insufficient"

Insurers demand WHO functional class (FC) III or IV, or a high-risk REVEAL Lite 2 score (≥8), before covering advanced therapies. If you are FC II or REVEAL intermediate (6–7), the denial reads "not severe enough" or "stable on current regimen," ignoring the fact that ESC/ERS 2022 guidelines target a low-risk profile—not merely preventing death—and recommend escalation for anyone not achieving FC I–II plus 6-minute walk distance (6MWD) >440 m, normal biomarkers, and REVEAL ≤5.

4. "Off-label or wrong WHO group"

For drugs approved only in PAH (Group 1), insurers auto-deny use in CTEPH (Group 4) unless the medication also has CTEPH approval (riociguat does; most ERAs do not). Similarly, Tyvaso inhaled received FDA expansion for PH-ILD (Group 3) in March 2021 based on the INCREASE trial, yet many plans still call Group 3 use "investigational." Sotatercept (Winrevair), approved March 26, 2024, for PAH FC II–III on background therapy, is frequently denied in FC IV or as monotherapy, both outside its label.

5. "Experimental / unproven"

This blanket phrase appears for sotatercept (the newest agent), upfront triple therapy, and any regimen not explicitly detailed in the plan's legacy medical policy, even when international consensus guidelines endorse it.

The Citations Insurers Respect

When you appeal, reference these landmark trials and guidelines by name and year—verbatim matches carry weight in peer-to-peer reviews and external appeals:

• ESC/ERS 2022 Pulmonary Hypertension Guidelines (updated hemodynamic definition mPAP ≥20 mmHg; 4-strata risk assessment at 3–6 months; treatment algorithm by initial risk).
• REVEAL Lite 2 (Benza Chest 2019) — the validated 8-variable risk calculator (FC, 6MWD, NT-proBNP, eGFR, systolic BP, heart rate, recent all-cause hospitalization, PDE5i/ERA use) that stratifies 1-year mortality: ≤5 low risk (~3%), 6–7 intermediate (~7–10%), ≥8 high (≥20%).
• STELLAR trial (Hoeper NEJM 2023) — pivotal study for sotatercept (Winrevair): 0.3 mg/kg SC increasing to 0.7 mg/kg every 3 weeks in PAH patients FC II–III already on 1–3 background therapies; met primary endpoint (change in 6MWD and PVR).
• AMBITION trial — upfront ambrisentan + tadalafil reduced morbidity/mortality by 50% versus monotherapy in treatment-naïve PAH; establishes dual-oral combination as first-line for intermediate-risk patients.
• GRIPHON trial — selexipag (Uptravi), oral prostacyclin-receptor agonist, reduced composite morbidity/mortality by 40%.
• SERAPHIN trial — macitentan (Opsumit) 10 mg daily.
• PATENT-1 (PAH) and CHEST-1 (CTEPH) — riociguat (Adempas), the only drug FDA-approved for both PAH and inoperable CTEPH.
• INCREASE trial — inhaled treprostinil (Tyvaso) improved 6MWD in PH-ILD (Group 3), leading to the March 31, 2021 FDA approval expansion—the first and only approved therapy for PH-ILD.
• TRIUMPH-1 — original Tyvaso approval in PAH (July 2009).
• FREEDOM-C/M and FREEDOM-EV — oral treprostinil (Orenitram) sustained-release.
• Barst NEJM 1996 — the landmark epoprostenol (Flolan) trial in severe PAH showing survival benefit; still the gold standard for high-risk patients.
• BREATHE-1 — bosentan (Tracleer), the first ERA.
• ARIES-1/2 — ambrisentan (Letairis).
• PHIRST — tadalafil (Adcirca) 40 mg daily.
• SUPER-1 — sildenafil (Revatio) 20 mg three times daily.

How to Argue Against Each Major Denial Reason

"No invasive hemodynamic confirmation"

Concrete steps:

1. Obtain and submit the full RHC report. It must document mPAP, PCWP, PVR, cardiac output (CO) and cardiac index (CI), right atrial pressure (RAP), and mixed venous oxygen saturation (SvO₂). For pre-capillary PH, the insurer needs mPAP ≥20 mmHg (2022 ESC/ERS threshold), PCWP ≤15 mmHg, and PVR ≥2 Wood units.

2. Include the date of catheterization. If the RHC is older than 12 months, insurers may call it "stale"; if treatment has changed since the cath, ask your PH specialist whether repeat RHC or updated echo/biomarkers are needed to prove persistent elevation.

3. Cite ESC/ERS 2022 hemodynamic criteria explicitly: "Per 2022 ESC/ERS guidelines, pre-capillary pulmonary hypertension is defined by right-heart catheterization showing mPAP ≥20 mmHg, PCWP ≤15 mmHg, and PVR ≥2 WU. Patient's RHC on [date] met all three criteria (mPAP ___, PCWP ___, PVR ___ WU)."

4. If vasoreactivity testing was performed (acute response to inhaled nitric oxide or IV epoprostenol during RHC), include the result. A positive Sitbon vasoreactivity response (fall in mPAP ≥10 mmHg to an absolute mPAP ≤40 mmHg without drop in cardiac output) identifies calcium-channel blocker (CCB) candidates; a negative test confirms the need for advanced PAH therapies and rules out CCB monotherapy.

"Step therapy not met"

Concrete steps:

1. Document every prior PAH drug tried: name, dose, duration, and objective outcomes (6MWD, WHO FC, NT-proBNP, REVEAL Lite 2 score) before and after.

2. Show clinical worsening or failure to reach low-risk goals. ESC/ERS 2022 defines treatment success as achieving low risk at 3–6-month reassessment: FC I–II, 6MWD >440 m, NT-proBNP <300 pg/mL (or BNP <50), RAP <8 mmHg, CI ≥2.5 L/min/m², REVEAL Lite 2 ≤5. If your metrics remain intermediate (e.g., REVEAL 6–7, 6MWD 300–440 m, NT-proBNP 300–1,400 pg/mL, FC II–III) or high (REVEAL ≥8, 6MWD <165 m, FC IV, NT-proBNP >1,400 pg/mL), state: "Patient failed to achieve low-risk status per ESC/ERS 4-strata model on [current regimen], warranting escalation."

3. Invoke upfront-combination evidence when applicable. If you are treatment-naïve and REVEAL intermediate or high, cite AMBITION: "The AMBITION trial demonstrated that upfront dual therapy with ambrisentan plus tadalafil reduced morbidity/mortality by 50% compared with monotherapy. Forcing sequential monotherapy contradicts level-I evidence and delays achievement of low-risk goals."

4. For parenteral prostacyclins in high-risk patients, cite Barst 1996 and ESC/ERS recommendations: "Continuous IV epoprostenol (Flolan) remains the only therapy with demonstrated survival benefit in severe PAH (Barst NEJM 1996). Current guidelines recommend parenteral prostacyclin—often as part of triple therapy—for high-risk patients (REVEAL ≥8, FC IV, or rapidly progressive disease)."

5. If the denial blocks Uptravi or Orenitram after you've tried an ERA and PDE5i, point to your combination-failure data: "Despite 4–6 months on dual oral therapy (macitentan + tadalafil), patient remained REVEAL 7 (intermediate-high risk), 6MWD 320 m, NT-proBNP 980 pg/mL, FC III—mandating prostacyclin-pathway escalation per GRIPHON and ESC/ERS treatment algorithm."

"Functional class / risk score insufficient"

Concrete steps:

1. Submit a current REVEAL Lite 2 calculation broken down by component (FC, 6MWD, NT-proBNP, eGFR, systolic BP, heart rate, all-cause hospitalization in past 6 months, PDE5i/ERA use). Even if your total is 6–7 (intermediate), explain: "ESC/ERS guidelines aim for low-risk status (REVEAL ≤5), not merely avoiding imminent death. Intermediate-risk patients have ~7–10% 1-year mortality and 20–40% risk of clinical worsening; treatment escalation at this stage is standard of care."

2. Highlight trend over time. If your 6MWD fell from 420 m to 310 m, or NT-proBNP rose from 150 to 800 pg/mL on current therapy, state: "Objective markers show disease progression despite current regimen, fulfilling criteria for escalation."

3. Use FC II language carefully. WHO FC II means "slight limitation of physical activity"—you are comfortable at rest but ordinary activity causes dyspnea or fatigue. Insurers often read FC II as "mild" and deny advanced drugs. Counter: "FC II patients who do not achieve low-risk biomarkers and walk distance remain at significant risk of hospitalization and right-heart failure. STELLAR enrolled FC II–III PAH patients on background therapy, demonstrating benefit of sotatercept in this population."

4. If your specialist has documented high-risk features (e.g., syncope, rapidly progressive symptoms, right-heart failure signs like ascites or elevated jugular venous pressure, severely reduced CI <2.0 L/min/m²), list them: "Patient exhibits clinical signs of advanced disease (syncope, pericardial effusion, CI 1.8 L/min/m²) warranting immediate escalation regardless of FC label."

"Off-label or wrong WHO group"

Concrete steps:

1. Confirm the WHO group in writing. Your appeal letter should state: "Right-heart catheterization confirmed pre-capillary PH (mPAP ≥20, PCWP ≤15, PVR ≥2 WU). Workup excluded left-heart disease (normal LVEF, no significant valvular disease, E/e′ <8), excluded parenchymal lung disease sufficient to cause PH (high-resolution CT showed no significant ILD/COPD), and ventilation-perfusion scan ruled out chronic thromboembolic disease. Patient meets criteria for WHO Group 1 PAH, subtype [idiopathic / heritable / connective-tissue disease–associated / etc.]."

2. For CTEPH (Group 4): Only riociguat (Adempas) is FDA-approved for both PAH and CTEPH (PATENT-1 and CHEST-1 trials). If an insurer denies an ERA or PDE5i in CTEPH, note whether the patient is inoperable or has residual PH post-pulmonary thromboendarterectomy (PTE), and cite: "Although [drug] label specifies PAH, international guidelines and expert consensus support ERA/PDE5i use in inoperable CTEPH and persistent PH post-PTE, particularly when riociguat alone is insufficient."

3. For PH-ILD (Group 3): Tyvaso (inhaled treprostinil) has FDA approval for PH-ILD as of March 31, 2021, based on INCREASE. If denied, write: "The INCREASE trial (NEJM 2021) demonstrated improved 6MWD in patients with PH associated with interstitial lung disease, leading to FDA approval. This is the only approved therapy for WHO Group 3 PH-ILD. Patient's hemodynamics (mPAP ___, PVR ___) and imaging confirm PH-ILD, meeting label indication."

4. For sotatercept (Winrevair): The March 26, 2024 FDA approval specifies PAH (Group 1), FC II–III, on background therapy. If you are FC IV or monotherapy-naïve, the insurer will cite off-label. In that case: escalate first to on-label background (ERA and/or PDE5i), then re-submit; or, if clinically you are FC II–III on background, ensure your prescriber's letter says so explicitly and cites STELLAR.

"Experimental / unproven"

Concrete steps:

1. For sotatercept, attach the FDA approval letter summary or cite the March 26, 2024 approval by name: "Winrevair (sotatercept-csrk) received FDA approval March 26, 2024, for pulmonary arterial hypertension WHO FC II–III to improve exercise capacity. Pivotal trial STELLAR (Hoeper NEJM 2023) showed significant improvement in 6MWD and reduction in PVR versus placebo in patients on 1–3 background PAH therapies."

2. For upfront triple therapy (ERA + PDE5i + parenteral prostacyclin started simultaneously or rapidly), reference ESC/ERS 2022 and TRITON/other registry data: "Current ESC/ERS guidelines state that high-risk patients (REVEAL ≥8, FC IV, severe hemodynamics) should be considered for initial triple combination therapy, including a parenteral prostacyclin. This approach is standard practice at accredited Pulmonary Hypertension Care Centers."

3. If the plan's medical policy is outdated (e.g., still uses mPAP ≥25 mmHg or does not recognize REVEAL Lite 2), write: "The insurer's policy appears to rely on superseded definitions. The 2022 ESC/ERS guidelines lowered the hemodynamic threshold to mPAP ≥20 mmHg and adopted risk-stratification tools (REVEAL Lite 2) to guide therapy intensity. Adherence to current evidence-based standards is both medically necessary and required under [state insurance law / ACA mandates for coverage of effective treatments]."

4. Engage your PH specialist in a peer-to-peer call. Insurers often reverse "experimental" denials when a pulmonologist or cardiologist from an accredited PH center walks the medical director through STELLAR, AMBITION, GRIPHON, or INCREASE by name and explains why the requested regimen matches consensus guidelines.

What We Do

We help patients compile the hemodynamic data, risk scores, prior-therapy documentation, and evidence citations that turn vague denials into winnable appeals. Our service organizes your RHC reports, calculates your REVEAL Lite 2 score, drafts letters citing the specific trials and guidelines your insurer's medical reviewers recognize, and coordinates with your PH specialist to prepare for peer-to-peer reviews. We do not replace your physician, but we ensure that every appeal is built on the same rigorous evidence base that accredited Pulmonary Hypertension Care Centers use every day—so the insurer sees not an "experimental" request, but a standard-of-care imperative backed by NEJM-level data and international consensus.

Sources

1. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022;43(38):3618–3731.

2. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL Risk Score Calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest 2019;156(2):323–337.

3. Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med 2023;388(16):1478–1490. [STELLAR]

4. Galiè N, Barberà JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015;373(9):834–844. [AMBITION]

5. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 2015;373(26):2522–2533. [GRIPHON]

6. Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369(4):330–340. [PATENT-1]

7. Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013;369(4):319–329. [CHEST-1]

8. Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med 2021;384(4):325–334. [INCREASE]

9. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010;55(18):1915–1922. [TRIUMPH-1]

10. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334(5):296–301.

11. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346(12):896–903. [BREATHE-1]

12. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117(23):3010–3019. [ARIES-1/2]

13. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369(9):809–818. [SERAPHIN]

14. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119(22):2894–2903. [PHIRST]

15. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353(20):2148–2157. [SUPER-1]

16. US Food and Drug Administration. Winrevair (sotatercept-csrk) approval letter. March 26, 2024.